arrow
L

Lisa Bodei

Memorial Sloan Kettering Cancer Center
H指数:70
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)

非功能性晚期GEP-NENs的管理临床实践指南:意大利医学肿瘤学会(AIOM)与意大利神经内分泌肿瘤学会(ITANET)合作,采用GRADE方法进行证据评估和推荐。

2025-11-120
OAAI
Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial

[177Lu]Lu-DOTATATE在晚期中肠神经内分泌肿瘤患者中的剂量测定:来自III期NETTER-1试验子研究的结果

2025-02-131
PRE
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force
2024-05-163
PRE
A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

1期,开放标签,剂量递增研究,以评估治疗性放射性药物131I-MIP-1095治疗转移性去势抵抗性前列腺癌的安全性和耐受性

2023-11-012
PRE
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs

在核肿瘤学的日常临床实践中实现放射性药物治疗的个体化剂量: 克服对肿瘤和关键器官的辐射吸收剂量的异质性

2023-09-152
OAAI
Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer

[177Lu]Lu-PSMA-617放射性药物联合立体定向放疗治疗寡转移去势敏感型前列腺癌的病灶剂量学

2023-08-314
OA
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

2021国家癌症研究所神经内分泌肿瘤临床试验计划会议共识报告

2023-05-311
OA
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

使用177lu标记的PSMA靶向放射配体疗法 (177Lu-PSMA-RLT) 的EANM/SNMMI联合程序指南

2023-05-2982
OAAI